Creighton Model FertilityCare System
||The neutrality of the style of writing in this article is questioned. (July 2012)|
||This article contains content that is written like an advertisement. (July 2012)|
|Creighton Model / FertilityCare|
|Birth control type||Behavioral|
|Failure rates (first year)|
|Typical use||3.2%(J Reprod Med 1998;43:495-502)|
|User reminders||Accurate instruction & daily charting are key.|
|Advantages and disadvantages|
|Benefits||Low direct cost;
no side effects;
in accord with Catholic teachings;
may be used to aid pregnancy achievement
The Creighton Model FertilityCare System (Creighton Model, FertilityCare, CrMS) is a form of natural family planning which involves identifying the fertile period during a woman's menstrual cycle. The Creighton Model was developed by Dr Thomas Hilgers, the founder and director of the Pope Paul VI Institute. This model, like the Billings ovulation method, is based on observations of cervical mucus to track fertility.
Dr Thomas Hilgers began research in 1976 which led to the development of the Creighton Model FertilityCare System, which was first fully described (as the Creighton Model) in 1980. In 1981, the American Academy of Natural Family Planning was founded to promote use of the Creighton Model as a form of natural family planning (the term for methods of family planning approved by the Roman Catholic church). In 1985, Hilgers created the Pope Paul VI Institute to medically support the directives given by Pope Paul VI in Humanae Vitae: On the Regulation of Birth.
In 1991, Hilgers self-published a manual titled The Medical Applications Of Natural Family Planning: A Physician’s Guide to NaProTECHNOLOGY through his Pope Paul VI Institute Press. NaProTechnology is described as Natural Procreative Technology. In 2001, the AANFP was renamed the American Academy of FertilityCare Professionals, to reflect the relabeling of the Creighton Model as FertilityCare. In 2004, Hilgers self-published a reference manual titled The Medical and Surgical Practice of NaProTECHNOLOGY. Hilgers refers to the Creighton Model FertilityCare System as "the foundational family planning system to NaProTechnology".
Hilgers describes the Creighton Model as being based on "a standardized modification of the Billings ovulation method", which was developed by John and Evelyn Billings in the 1960s. The Billingses issued a paper refuting the claim that the CrMS represents a standardization of the BOM. They are two different methods and should not be seen as interchangeable.
A foundational principle of Dr. Hilgers’ teaching is the concept of fertility appreciation: “The ability to mutually value, respect, and understand one’s fertility.” (Hilgers, 2004). With the CrMS, it is important to understand that a couple’s fertility is not to be seen as something that must be cured or suppressed, but as an essential component of health and wellness. For these principles, NaProTechnology and CrMS work by gaining understanding of a woman’s menstrual and fertility cycles, and using this understanding of certain biological indications in order to avoid or achieve a pregnancy. By using the information learned through the CrMS, procreative and gynecologic health may be encouraged and monitored by women throughout their lives.
The basis of CrMS is observation of biological signs that indicate fertile or infertile times in a woman’s fertility cycle. These biological signs include observation of different types of cervical mucus and various bleeding patterns. As ovulation approaches, mucus production, quantity, stretch ability, and clarity increase as a result of rising estrogen levels. Once ovulation has occurred, the mucus will change, becoming more cloudy and thick, due to the rise in progesterone. Through observation and careful charting of these biological signs, a couple may effectively utilize this information in monitoring fertility.
Each new cycle starts with the menses. Due to the possibility of a short pre-ovulation phase, any vaginal bleeding is considered fertile when trying to avoid pregnancy. Any brown bleeding at the end of a period may be a sign of a progesterone deficiency. On light, very light, or days of brown bleeding, it is important to remember to check for mucus. As the estrogen levels rise, mucus is produced. Any mucus that is either clear, stretchy or lubricating is considered "peak-type" mucus, and days where it is noticed are considered fertile, as are the three days after. Any days where no mucus is observed or it is not peak-type (or in the count of three) are considered infertile and can be used for sex (if trying to avoid pregnancy). In the case of persistent cervical mucus, a different protocol is used.
To test for cervical mucus, the Creighton model uses only bathroom tissue. It must be folded, not crumpled. It is important to wipe front to back in order to feel for lubrication. This is to be done before and after every time using the restroom, including showers and shortly before bed.
Blood tests for estrogen levels prior to ovulation and for both Progesterone and estrogen levels after ovulation, ultrasound follicular tracking, and other diagnostic procedures, can be accurately timed according to the woman's cycle, using the data recorded on a couple's fertility chart. This allows doctors to make a more precise diagnosis of abnormalities, e.g. subtle hormonal deficiencies, various ovulation defects etc.
Doctors can use the fertility charts which couples are taught to keep as the basis for further investigations if needed.
Important to note is that women with fertility cycles not considered “normal” (such as women who are breast-feeding, have long or irregular cycles, are coming off contraceptive pills, have continuous discharge, anovulatory states or premenopause) can still successfully use the CrMS to regulate and monitor their abnormal fertility cycles and/or underlying medical conditions.
As a form of fertility awareness or natural family planning, the CrMS may be used[weasel words] to avoid pregnancy, or to increase chances of conception depending on the couple's intentions. The CrMS is used in conjunction with NaProTechnology (Natural Procreative Technology)[vague][clarification needed] to treat infertility. It is also used to treat other problems[peacock term] besides infertility such as:
- Menstrual cramps
- Premenstrual syndrome (PMS)[unreliable source?][self-published source]
- Ovarian cysts
- Irregular or abnormal bleeding
- Polycystic ovarian disease[unreliable source?][self-published source]
- Repetitive miscarriage
- Postpartum depression[unreliable source?][self-published source]
- Prematurity prevention
- Hormonal abnormalities
- Chronic discharges
- Other health problems[peacock term]
Effectiveness in avoiding pregnancy
The effectiveness of the CrMS can be assessed two ways. Perfect use or method effectiveness rates only include people who follow all observational rules, correctly identify the fertile phase, and refrain from intercourse on days identified as fertile. Actual use, or typical use effectiveness rates are of all women intending to avoid pregnancy by using CrMS, including those who fail to meet the "perfect use" criteria.
The Pope Paul VI Institute reports a perfect-use effectiveness rate of 99.5% in the first year. In clinical studies of the CrMS conducted at the Pope Paul VI Institute, researchers excluded most pregnancies from the typical-use rate calculation, on the grounds that they believed the affected couples had used the method to deliberately attempt pregnancy. The Institute reports a typical-use effectiveness of 96.8% in the first year. Most studies of similar systems do not exclude such pregnancies from the typical-use failure rate. NaproTechnology is more than twice[peacock term][weasel words] a successful as IVF. Also, lower risk[weasel words] of multiples have been seen in comparison to ART and there has been no observed risk of OHSS. It also costs less than IVF (Hilger, 2006).[full citation needed]
- Use of natural hormones and other medications to correct any hormonal disturbances or ovulation abnormality.
- Use of medications if necessary to correct any other abnormalities e.g. cervical mucus deficiency, biochemical or haematological deficiencies, endocrine (glandular) deficiencies etc. to restore normal physiologic function, and thereby enhance fertility.
- Referral to a gynaecologist if there are physical abnormailities needing surgery, for example
- Creighton Model
- American Academy of FertilityCare Professionals
- Some Clarifications Concerning NaProTECHNOLOGY and the Billings Ovulation Method
- "Premenstrual Syndrome". November 2012.
- "Surgical NaProTECHNOLOGY". November 2012.
- "Postpartum Depression". November 2012.
- Hatcher, RA; Trussel J; Stewart F et al. (2000). Contraceptive Technology (18th Edition ed.). New York: Ardent Media. ISBN 0-9664902-6-6.
- "CREIGHTON MODEL FertilityCare System: Effectiveness of the System". creightonmodel.com. Retrieved 2008-07-16.
- Use effectiveness of the Creighton model ovulation...[J Obstet Gynecol Neonatal Nurs. 1994] - PubMed Result
- Weschler, Toni (2002). Taking Charge of Your Fertility (Revised Edition ed.). New York: HarperCollins. pp. 349–350. ISBN 0-06-093764-5.
- Kippley, John; Sheila Kippley (1996). The Art of Natural Family Planning (4th addition ed.). Cincinnati, OH: The Couple to Couple League. pp. 141–142. ISBN 0-926412-13-2.
Hilgers, Thomas W.,M.D., The NaPro Technology Revolution: unleashing the Power in a Woman's Cycle. New York: Beaufort Books, 2010. Print.
Hilgers, Thomas W. The Medical & Surgical Practice of NaProTECHNOLOGY. Omaha: Pope Paul VI Institute, 2004. N. pag. Print.
Moore, Keith L., T,V.N Persaud, and Mark G. Torchia. Before we are Born Essentials of Embryology and Birth Defects. 8th ed. Philadelphia: Elsevier Inc., 2013. Print.
Unleashing the Power of a Woman's Cycle. Pope Paul VI Institute, 2006. Web. 14 Nov. 2012. <http://www.naprotechnology.com/index.html>.
Jemelka, B. E., & Parker, D. W., & Mirkes, R. (2013). State of the Art and Science NapProTECHNOLOGY and Conscientious OB/GYN Medicine. American Medical Association Journal of Ethics, 15. Retrieved from http://virtualmentor.ama-assn.org/2013/03/stas1-1303.html
Hilgers, T. W. (2011). The New Women’s Health Science of NaProTECHNOLOGY. Archives of Perinatal Medicine, 17(4). Retrieved from http://www.fertilitycare.net/documents/APM174-2-Hilgers.pdf
Stanford, J. B., & Parnell, T. A., & Boyle, P. C. (2008). Outcomes from Treatment of Infertility with Natural Procreative Technology in an Irish General Practice, JABFM, 21 (5). Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18772291
J Reprod Med 1998;43:495-502
- Creighton Model official site
- Pope Paul VI Institute for the Study of Human Reproduction
- Interview With Dr. Thomas Hilgers, Director of the Pope Paul VI Institute
- NaProTechnology: A Rational Approach to Reproductive Medicine